Modulation of Tolerance and Autoimmunity by Inhibitory Receptors
Modulation of Tolerance and Autoimmunity by Inhibitory Receptors
批准号:
8854452
负责人:
Arlene H. Sharpe
金额:
$58.7万
依托单位国家:
美国
项目类别:
财政年份:
2015
资助国家:
美国
项目状态:
已结题
起止时间:
2015-05-15 至 2020-04-30
关键词:
Adoptive TransferAgeAntibodiesAntiviral AgentsAutoantigensAutoimmune DiabetesAutoimmune DiseasesAutoimmune ProcessAutoimmunityCD4 Positive T LymphocytesCD8B1 geneCellsChronicDataDevelopmentDiabetes MellitusEquilibriumExperimental Autoimmune EncephalomyelitisGene DeletionGenerationsGenesGeneticImmuneImmune responseImmunityImmunotherapyInbred NOD MiceInfectionInsulin-Dependent Diabetes MellitusKnockout MiceLeadLearningMalignant NeoplasmsMediatingMediator of activation proteinModelingMolecularMusOutcomePathologyPathway interactionsPhenotypePlayPopulationPublishingRegulatory T-LymphocyteRelative (related person)RiskRoleSelf ToleranceSignal PathwaySignal TransductionT-Cell ActivationT-LymphocyteTestingTherapeuticTherapeutic InterventionTissuesTransgenic OrganismsViralbasecell typeexhaustexhaustionimmunopathologynovelpreventprogramsreceptorsystemic autoimmune diseasetherapeutic targettumor
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY
PD1 and LAG3 both play critical roles in controlling T cell tolerance, preventing autoimmunity, and limiting
immune-mediated tissue damage. Combined genetic deficiency of PD1 and LAG3 in mice results in lethal
systemic autoimmunity, demonstrating critical PD1/LAG3 synergies in tolerance. PD1 and LAG3 also are
mediators of T cell exhaustion, and synergize to limit viral or tumor control. PD1 and LAG3 are promising
therapeutic targets, but little is know about their mechanisms of action or how synergy is mediated. Project 1
will investigate mechanisms by which PD1 and LAG3 interactions regulate the balance between pathogenic
and protective immune responses in autoimmunity, using the experimental autoimmune encephalomyelitis
(EAE) and type 1 diabetes models. Our overall hypothesis is that PD1 and LAG3 have synergistic effects in
tolerance and autoimmunity by controlling functions of self-reactive CD4+ FoxP3- T cells and protective FoxP3+
Treg cells. We will use novel conditional PD1 and LAG3 knockout mice crossed to cell type-specific Cre lines to
test this hypothesis: Aim 1: What are the relative roles of PD1 and LAG3 in controlling the generation and
function of Treg cells? We will test the hypothesis that interactions between PD1 and LAG3 control Treg
function and stability, and thereby impact self tolerance. Surprisingly, our preliminary data show that mice
lacking LAG3 and/or PD1 in Treg develop ameliorated autoimmune disease. We will analyze the relative roles
of PD1 and LAG3 in Treg, and determine how they contribute to Treg function in EAE and NOD diabetes. We will
examine if there are interactions between LAG3/PD1 in the same or distinct Treg or between PD1/LAG3 on Treg
and other cell types, and determine molecular pathways associated with LAG3/PD1 interactions in Treg during
autoimmunity. Aim 2: What are the relative and synergistic roles of PD1 and LAG3 in regulating self-reactive
CD4+ T cells? In contrast to ameliorated autoimmunity in mice lacking PD1 and/or LAG3 on Treg, loss of LAG3
and/or PD1 on all T cells accelerates autoimmunity. These disparate phenotypes lead us to hypothesize that
PD1 and LAG3 synergize to have a dominant effect on CD4+ T cells in mediating tolerance to self antigens. To
understand these differences, separate analyses of Treg and FoxP3- T cells are needed. In this aim we will
determine the relative contributions of PD1 and LAG3 in regulating self-reactive CD4+ T cells. We will
determine if there are synergies between LAG3/PD1 in CD4+ cells, if LAG3 and PD1 operate in the same or
distinct CD4+ T cells, and molecular pathways associated with interactions between LAG3/PD1 in CD4+ T cells
in autoimmune disease. Project 1 will collaborate with Project 2 to compare the impact of disruption of
PD1/LAG3 signals in Treg in autoimmunity and cancer, and Project 3 to compare PD1/LAG3 interactions in
autoreactive and exhausted CD4+ T cells. Project 1 will use Core B for mice, Core C for transcriptional
analyses, Core D for immunopathology studies, and Core A for statistical support.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Defining regulators of immunity to acute infection using CRISPR screens
-
批准号:10210502
-
项目类别:
-
资助金额:$10.99万
-
财政年份:2020
-
负责人:Arlene H. Sharpe
-
依托单位:
Abbreviated targeted therapy to improve anti-PD-1 inhibitor efficacy in melanoma
-
批准号:10153453
-
项目类别:
-
资助金额:$38.06万
-
财政年份:2018
-
负责人:Arlene H. Sharpe
-
依托单位:
Project 2: Measuring and modeling the tumor and immune microenvironment before and during therapy and at the time of drug resistance
-
批准号:10343840
-
项目类别:
-
资助金额:$30.14万
-
财政年份:2018
-
负责人:Arlene H. Sharpe
-
依托单位:
Abbreviated targeted therapy to improve anti-PD-1 inhibitor efficacy in melanoma
-
批准号:9906872
-
项目类别:
-
资助金额:$38.05万
-
财政年份:2018
-
负责人:Arlene H. Sharpe
-
依托单位:
Abbreviated targeted therapy to improve anti-PD-1 inhibitor efficacy in melanoma
-
批准号:9576657
-
项目类别:
-
资助金额:$39.83万
-
财政年份:2018
-
负责人:Arlene H. Sharpe
-
依托单位:
Defining regulators of immunity to acute infection using CRISPR screens
-
批准号:10207344
-
项目类别:
-
资助金额:$229.25万
-
财政年份:2017
-
负责人:Arlene H. Sharpe
-
依托单位:
Project 1: CRISPR screens to discover regulators of CD8 and CD4 cell fates and function
-
批准号:10207349
-
项目类别:
-
资助金额:$86.54万
-
财政年份:2017
-
负责人:Arlene H. Sharpe
-
依托单位:
Defining regulators of immunity to acute infection using CRISPR screens
-
批准号:9380804
-
项目类别:
-
资助金额:$246.29万
-
财政年份:2017
-
负责人:Arlene H. Sharpe
-
依托单位:
Core D: Mouse Perturbation Core
-
批准号:10207348
-
项目类别:
-
资助金额:$81.28万
-
财政年份:2017
-
负责人:Arlene H. Sharpe
-
依托单位:
Administrative Core
-
批准号:10207345
-
项目类别:
-
资助金额:$37.75万
-
财政年份:2017
-
负责人:Arlene H. Sharpe
-
依托单位:
Defining regulators of immunity to acute infection using CRISPR screens
-
批准号:10266219
-
项目类别:
-
资助金额:$10.99万
-
财政年份:2017
-
负责人:Arlene H. Sharpe
-
依托单位:
T Cell Costimulatory Pathways: Function and Interactions
-
批准号:9121451
-
项目类别:
-
资助金额:$3.96万
-
财政年份:2016
-
负责人:Arlene H. Sharpe
-
依托单位:
Project 1: Costimulation and Regulation of Anti-viral Immunity
-
批准号:9121455
-
项目类别:
-
资助金额:$53.35万
-
财政年份:2016
-
负责人:Arlene H. Sharpe
-
依托单位:
Project 1 - Modulation of Tolerance and Autoimmunity by Inhibitory Receptors
-
批准号:10023668
-
项目类别:
-
资助金额:$47.04万
-
财政年份:2015
-
负责人:Arlene H. Sharpe
-
依托单位:
Project 1 - Modulation of Tolerance and Autoimmunity by Inhibitory Receptors
-
批准号:10239110
-
项目类别:
-
资助金额:$45.63万
-
财政年份:2015
-
负责人:Arlene H. Sharpe
-
依托单位:
Project 1 - Modulation of Tolerance and Autoimmunity by Inhibitory Receptors
-
批准号:10670295
-
项目类别:
-
资助金额:$45.63万
-
财政年份:2015
-
负责人:Arlene H. Sharpe
-
依托单位:
Project 1 - Modulation of Tolerance and Autoimmunity by Inhibitory Receptors
-
批准号:10663576
-
项目类别:
-
资助金额:$45.63万
-
财政年份:2015
-
负责人:Arlene H. Sharpe
-
依托单位:
Role of Costimulation in Control of the Effector and Regulatory T Cell Balance
-
批准号:8289441
-
项目类别:
-
资助金额:$62.9万
-
财政年份:2011
-
负责人:Arlene H. Sharpe
-
依托单位:
Role of Immune Regulatory Pathways in BRAF Targeted Therapy In Melanoma
-
批准号:8555326
-
项目类别:
-
资助金额:$24.84万
-
财政年份:2011
-
负责人:Arlene H. Sharpe
-
依托单位:
Regulation of chronic viral infection by co-inhibitory pathways
-
批准号:8432766
-
项目类别:
-
资助金额:$12.68万
-
财政年份:2010
-
负责人:Arlene H. Sharpe
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: